---
input_text: 'Long-term bone outcomes in Italian patients with Gaucher disease type
  1 or type 3 treated with imiglucerase: A sub-study from the International Collaborative
  Gaucher Group (ICGG) Gaucher Registry. BACKGROUND: Gaucher disease (GD) is a lysosomal
  storage disorder. We evaluated the "real-world" effectiveness of first-line imiglucerase
  on long-term bone outcomes in Italian patients in the International Collaborative
  Gaucher Group (ICGG) Gaucher Registry. METHODS: Patients treated with imiglucerase
  for >=2 years and with bone assessments at baseline and during follow-up were selected.
  Data on bone pain, bone crises, marrow infiltration, avascular necrosis, infarction,
  lytic lesions, Erlenmeyer flask deformity, bone fractures, mineral density, and
  imiglucerase dosage were evaluated. RESULTS: Data on bone manifestations were available
  for 73 of 229 patients (31.9 %). Bone crises frequency decreased significantly from
  baseline to the most recent follow-up (p < 0.001), with some improvement observed
  in bone pain prevalence. Bone pain and bone crises prevalence decreased significantly
  from baseline at 2 to <4 and 4 to <6 years (all p < 0.05). A low median (25th, 75th
  percentile) baseline imiglucerase dosage was identified in patients reporting bone
  pain or bone crises (15.0 [13.7, 30.0] and 22.8 [17.5, 36.0] U/kg once every 2 weeks,
  respectively). CONCLUSION: Our study suggests that the management of GD in Italy,
  with regards to imiglucerase dosage, is suboptimal and confirms the need for clinicians
  to monitor and correctly treat bone disease according to best practice guidelines.'
raw_completion_output: |-
  primary_disease: Gaucher disease

  medical_actions: Treatment with imiglucerase; Monitoring bone disease; Following best practice guidelines

  symptoms: Bone pain; Bone crises; Marrow infiltration; Avascular necrosis; Infarction; Lytic lesions; Erlenmeyer flask deformity; Bone fractures; Altered mineral density

  chemicals: Imiglucerase

  action_annotation_relationships: Treatment with imiglucerase TREATS bone pain IN Gaucher disease; Treatment with imiglucerase TREATS bone crises IN Gaucher disease; Monitoring bone disease PREVENTS bone crises IN Gaucher disease; Monitoring bone disease PREVENTS bone pain IN Gaucher disease; Following best practice guidelines PREVENTS bone crises IN Gaucher disease; Following best practice guidelines PREVENTS bone pain IN Gaucher disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Following best practice guidelines PREVENTS bone pain IN Gaucher disease

  ===

extracted_object:
  primary_disease: MONDO:0018150
  medical_actions:
    - Treatment with imiglucerase
    - Monitoring bone disease
    - Following best practice guidelines
  symptoms:
    - HP:0002653
    - Bone crises
    - Marrow infiltration
    - HP:0010885
    - Infarction
    - HP:0002797
    - Erlenmeyer flask deformity
    - HP:0020110
    - Altered mineral density
  chemicals:
    - Imiglucerase
  action_annotation_relationships:
    - subject: Treatment
      predicate: TREATS
      object: HP:0002653
      qualifier: MONDO:0018150
      subject_extension: imiglucerase
    - subject: Treatment
      predicate: TREATS
      object: bone crises
      qualifier: MONDO:0018150
      subject_qualifier: with
      subject_extension: imiglucerase
    - subject: Monitoring bone disease
      predicate: PREVENTS
      object: bone crises
      qualifier: MONDO:0018150
    - subject: Monitoring bone disease
      predicate: PREVENTS
      object: HP:0002653
      qualifier: MONDO:0018150
    - subject: Following best practice guidelines
      predicate: PREVENTS
      object: bone crises
      qualifier: MONDO:0018150
    - subject: best practice guidelines
      predicate: PREVENTS
      object: HP:0002653
      qualifier: MONDO:0018150
named_entities:
  - id: MONDO:0002561
    label: Lysosomal Storage Disorders
  - id: CHEBI:135923
    label: Migalastat
  - id: HP:0001071
    label: Fabry disease
  - id: MONDO:0018150
    label: Gaucher Disease (GD)
  - id: HP:0001395
    label: liver fibrosis
  - id: HP:0001394
    label: cirrhosis
  - id: HP:0100626
    label: end-stage liver disease
  - id: HP:0001402
    label: hepatocellular carcinoma
  - id: MAXO:0001001
    label: gene therapy
  - id: MAXO:0001257
    label: vitamin E supplementation
  - id: MAXO:0010200
    label: abdominal ultrasonography
  - id: HP:0025464
    label: oxidative stress
  - id: CHEBI:33234
    label: vitamin E
  - id: CHEBI:566274
    label: malondialdehyde (MDA)
  - id: CHEBI:16856
    label: reduced glutathione (GSH)
  - id: MAXO:0009091
    label: Substrate reduction therapy (SRT)
  - id: HP:0002716
    label: Lymphadenopathy
  - id: HP:0001903
    label: Anemia
  - id: HP:0001873
    label: Thrombocytopenia
  - id: HP:0001433
    label: Hepatosplenomegaly
  - id: CHEBI:30884
    label: Glucosylceramide synthase (GCS) inhibitors
  - id: CHEBI:135590
    label: ambroxol
  - id: HP:0410281
    label: dyspepsia
  - id: HP:0002027
    label: abdominal pain
  - id: CHEBI:82752
    label: eliglustat
  - id: CHEBI:4177
    label: glucosylsphingosine
  - id: HP:0003281
    label: hyperferritinemia
  - id: HP:0011024
    label: gastrointestinal disorders
  - id: MONDO:0010526
    label: Fabry disease
  - id: HP:0002180
    label: neurodegeneration
  - id: MONDO:0009267
    label: Gaucher Disease Type 3
  - id: HP:0001251
    label: ataxia
  - id: HP:0001332
    label: dystonia
  - id: HP:0001337
    label: tremor
  - id: HP:0001250
    label: seizures
  - id: HP:0000939
    label: Osteoporosis
  - id: MONDO:0009265
    label: Gaucher disease type 1
  - id: MONDO:0005201
    label: Restrictive cardiomyopathy
  - id: HP:0001635
    label: cardiac failure
  - id: MAXO:0000950
    label: supportive care
  - id: HP:0001744
    label: splenomegaly
  - id: HP:0010885
    label: osteonecrosis
  - id: HP:0002653
    label: bone pain
  - id: MAXO:0000747
    label: Haematopoietic Stem Cell Transplantation (HSCT)
  - id: MAXO:0010030
    label: bone marrow transplantation (BMT)
  - id: HP:0011891
    label: postpartum hemorrhage (PPH)
  - id: HP:0005268
    label: miscarriage
  - id: MONDO:0100096
    label: COVID-19
  - id: HP:0003493
    label: positive ANA
  - id: HP:0000872
    label: Hashimoto thyroiditis
  - id: CHEBI:74066
    label: Immunoglobulin (Ig) M
  - id: HP:0031915
    label: stable
  - id: MAXO:0000127
    label: genetic testing
  - id: MAXO:0000752
    label: bone marrow aspiration
  - id: HP:0001876
    label: pancytopenia
  - id: HP:0100543
    label: cognitive impairment
  - id: HP:0002942
    label: thoracic kyphosis
  - id: HP:0000823
    label: delayed puberty
  - id: MAXO:0009003
    label: Preimplantation genetic testing (PGT)
  - id: MAXO:0000079
    label: Genetic counseling
  - id: CHEBI:18368
    label: glucocerebroside
  - id: MAXO:0000943
    label: dry blood spot (DBS) testing
  - id: CHEBI:71981
    label: Glucosphingosine (lyso-Gb1)
  - id: CHEBI:195532
    label: Glucosylceramide (GlcCer)
  - id: HP:0001298
    label: Brain disease
  - id: MAXO:0000110
    label: vitamin D supplementation
  - id: MAXO:0001077
    label: splenectomy
  - id: HP:0002756
    label: pathologic fractures
  - id: CHEBI:82594
    label: ferritin
  - id: CHEBI:27300
    label: vitamin D
  - id: MAXO:0001298
    label: therapy
  - id: HP:0000657
    label: oculomotor apraxia
  - id: HP:0000486
    label: squint
  - id: HP:0002240
    label: hepatomegaly
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0020172
    label: Adverse drug reactions (ADRs)
  - id: HP:0002013
    label: Vomiting
  - id: MAXO:0000647
    label: Chemotherapy
  - id: MAXO:0000014
    label: Radiation
  - id: CHEBI:28445
    label: Vincristine
  - id: CHEBI:28748
    label: Doxorubicin
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: CHEBI:5864
    label: Ifosfamide
  - id: CHEBI:4911
    label: Etoposide
  - id: HP:0012254
    label: Ewing sarcoma
  - id: CHEBI:36500
    label: glucosylceramide
  - id: HP:0032794
    label: myoclonic seizures
  - id: HP:0001268
    label: progressive cognitive decline
  - id: CHEBI:31198
    label: Ambroxol hydrochloride
  - id: MONDO:0019255
    label: Sphingolipidoses
  - id: MAXO:0000068
    label: transplantation
  - id: HP:0007018
    label: attention deficit
  - id: HP:0001871
    label: hematological abnormalities
  - id: HP:0006775
    label: multiple myeloma
  - id: MONDO:0019052
    label: Inborn Errors of Metabolism
  - id: HP:0000842
    label: Hyperinsulinism
  - id: HP:0000938
    label: Osteopenia
  - id: HP:0002797
    label: Lytic lesions
  - id: HP:0020110
    label: Bone fractures
